Emerging Therapeutic Potential of Polyphenols from Geranium sanguineum L. in Viral Infections, Including SARS-CoV-2

Biomolecules. 2024 Jan 19;14(1):130. doi: 10.3390/biom14010130.

Abstract

The existing literature supports the anti-inflammatory, antioxidant, and antiviral capacities of the polyphenol extracts derived from Geranium sanguineum L. These extracts exhibit potential in hindering viral replication by inhibiting enzymes like DNA polymerase and reverse transcriptase. The antiviral properties of G. sanguineum L. seem to complement its immunomodulatory effects, contributing to infection resolution. While preclinical studies on G. sanguineum L. suggest its potential effectiveness against COVID-19, there is still a lack of clinical evidence. Therefore, the polyphenols extracted from this herb warrant further investigation as a potential alternative for preventing and treating COVID-19 infections.

Keywords: COVID-19; Geranium sanguineum; poliphenols; viral infection.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19*
  • Flavonoids / pharmacology
  • Geranium*
  • Humans
  • Phenols / pharmacology
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use
  • Polyphenols / pharmacology
  • Polyphenols / therapeutic use
  • SARS-CoV-2
  • Virus Diseases* / drug therapy

Substances

  • Polyphenols
  • Flavonoids
  • Phenols
  • Antiviral Agents
  • Plant Extracts

Grants and funding

This research received no external funding.